The use of bevacizumab, popularly known as Avastin, for providing benefit to diabetic patients with macular edema as well as people who develop cystoid macular edema after cataract surgery has been reported by the journal Ophthalmology.

Bevacizumab is presently used to treat some forms of cancer.

From Sciencedaily.com:

Treating DMME with bevacizumab (Avastin), an anti-vascular endothelial growth factor (anti-VEGF) medication that inhibits abnormal blood vessels, was studied in115 patients (139 eyes) by the Pan-American Collaborative Retina Study Group, led by J. Fernando Arevalo, MD, of the Caracas Central Ophthalmologic Clinic, Venezuela. Within one month of the initial intravitreal bevacizumab (IVB) injections, improvement could be detected. By the end of the 24 month follow-up period vision had improved in 51.8 percent of eyes and 97.1 percent of eyes were either stable or improved. No serious adverse effects occurred.

The Pan-American Collaborative Retina Study Group also reviewed the use of bevacizumab in patients with post-cataract surgery cystoid macular edema (CME) who had not responded to standard treatment. Twenty to 30 percent of all cataract surgery patients develop CME, in which the macula swells as fluid-filled cysts form. Usually the condition resolves without treatment and causes no permanent vision loss, but in a small percentage of patients vision remains worse than 20/40 and treatment is needed. Standard treatments include steroids, non-steroidal anti-inflammatories (NSAIDs), other medications, or surgery.

It is important to note here that diffuse DME (DDME) is often resistant to laser and other standard treatments and treating DDME with bevacizumab is an amicable treatment options with no serious adverse effects.

Tags: Avastin, bevacizumab, steroids

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids